+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 65Years +
All Genders
ID06138561

Study of Treatment Approaches and Geriatric Assessments in Older Adults With Metastatic Bladder Cancer Who Cannot Receive Cisplatin

Led by Dana-Farber Cancer Institute · Updated on 2026-02-17

180

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying how best to treat older adults with advanced bladder cancer who may not tolerate all chemotherapy drugs. This study focuses on patients deemed ineligible for cisplatin treatment and evaluates the role of the Geriatric-8 survey in predicting treatment outcomes. The study also looks at how different treatments affect quality of life in this older, at-risk population. Participants receive standard non-cisplatin therapies such as carboplatin-based chemotherapy, enfortumab vedotin plus pembrolizumab, or immunotherapy. The study involves baseline and regular follow-up visits over 8 months, including questionnaires about quality of life and adverse events. Optional follow-up phone calls occur every 6 months for up to 3 years. During participation, patients complete surveys at baseline and every 3 weeks by phone or in office. Researchers monitor patient-reported side effects, quality of life, treatment changes, and acute care visits. The main outcomes measured include quality of life and adverse events over 8 months, with longer-term monitoring of survival and other health measures up to 3 years.

CONDITIONS

Brief Title

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Research Team

J

Joaquim Bellmunt, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here